Department of Obstetrics and Gynaecology, Department of Surgical Sciences, University of Cagliari , Monserrato , Italy.
Maternal Child Department, University Hospital of Cagliari , Monserrato , Italy.
Expert Opin Pharmacother. 2019 Nov;20(16):2019-2032. doi: 10.1080/14656566.2019.1654996. Epub 2019 Aug 26.
: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer. : Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies. : Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies.
子宫内膜癌 (EC) 是全球最常见的妇科癌症之一。EC 的金标准治疗方法肯定是手术,而且在疾病的早期阶段可能是唯一的治疗方法。为了提高非早期 EC 的治疗效果,通常会采用辅助治疗,但这尚未标准化。辅助治疗选择可以包括放疗、化疗或两者的联合治疗。辅助化疗可能适用于高危Ⅰ期和Ⅱ期或晚期 EC。目前正在进行多项临床试验,试图确定最佳辅助治疗方法。此外,化疗是晚期不可切除、转移性或复发性子宫内膜癌的一线治疗方法。
在此,作者回顾了治疗子宫内膜癌的一线化疗药物,并提供了他们对这些疗法的专业观点。
化疗是晚期/复发性 EC 的基础。需要更多的证据来描述辅助化疗的作用。未来的研究应考虑基因组和分子异质性,以确定更有效的靶向治疗方法。